Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Just eight seconds into the start of the 2025 award show season, Nikki Glaser, the host of the 82nd Golden Globes, dubbed the ...

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...

Dec. 21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.